Thu, August 23, 2012
Wed, August 22, 2012
[ Wed, Aug 22nd 2012 ]: Market Wire
Inergetics Shareholder Update
Tue, August 21, 2012
Mon, August 20, 2012
Sat, August 18, 2012
Fri, August 17, 2012
Thu, August 16, 2012
Wed, August 15, 2012
Tue, August 14, 2012
Mon, August 13, 2012
Fri, August 10, 2012
Thu, August 9, 2012
Wed, August 8, 2012
Tue, August 7, 2012
Mon, August 6, 2012
Fri, August 3, 2012
Thu, August 2, 2012
[ Thu, Aug 02nd 2012 ]: Market Wire
00 p.m. EDT
Wed, August 1, 2012
[ Wed, Aug 01st 2012 ]: Market Wire
Head of European Operations
Tue, July 31, 2012

HeartWare Presentation At The Canaccord Genuity 32nd Annual Growth Conference To Be Webcast


  Copy link into your clipboard //health-fitness.news-articles.net/content/2012/ .. 32nd-annual-growth-conference-to-be-webcast.html
  Print publication without navigation Published in Health and Fitness on by Market Wire
          🞛 This publication is a summary or evaluation of another publication

HeartWare Presentation At The Canaccord Genuity 32nd Annual Growth Conference... -- FRAMINGHAM, Mass. and SYDNEY, Aug. 10, 2012 /PRNewswire/ --

HeartWare Presentation At The Canaccord Genuity 32nd Annual Growth Conference To Be Webcast

[ ]

FRAMINGHAM, Mass. and SYDNEY, Aug. 10, 2012 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: [ HTWR ] - ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to present at the Canaccord Genuity 32nd Annual Growth Conference at 8:00 a.m. EDT on Wednesday, August 15, 2012.  The conference is being held August 14-16, 2012 at the InterContinental Hotel in Boston.

A live webcast of the Company's presentation at the conference will be available via a link provided at [ www.heartware.com ].  A replay of the webcast will be available for 90 days at the site after the presentation.

About HeartWare International

HeartWare International develops and manufactures miniaturized implantable heart pumps, or ventricular assist devices, to treat Class IIIB / IV patients suffering from advanced heart failure.  The HeartWare® Ventricular Assist System features the HVAD® pump, a small full-output circulatory support device (up to 10L/min flow) designed to be implanted next to the heart, avoiding the abdominal surgery generally required to implant competing devices.  HeartWare has received CE Marking for the HeartWare System in the European Union and TGA approval in Australia.  The device is currently the subject of United States clinical trials for two indications: bridge-to-transplant and destination therapy.  For additional information, please visit [ www.heartware.com ].

HeartWare International, Inc. is a member of the Russell 2000® and its securities are publicly traded on The NASDAQ Stock Market and the Australian Securities Exchange.

HEARTWARE, HVAD, MVAD and HeartWare logos are registered trademarks of HeartWare, Inc.

For further information:
Christopher Taylor
HeartWare International, Inc.
Email: [ ctaylor@heartwareinc.com ]
Phone: +1 508 739 0864

SOURCE HeartWare International, Inc.



[ Back to top ]

RELATED LINKS
[ http://www.heartware.com ]


Publication Contributing Sources